A-METHAPRED Drug Patent Profile

Which patents cover A-methapred, and when can generic versions of A-methapred launch?

A-methapred is a drug marketed by Abbott, Hospira, and Hospira Inc. and is included in fourteen NDAs.

The generic ingredient in A-METHAPRED is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for A-methapred

A generic version of A-METHAPRED was approved as methylprednisolone sodium succinate by FRESENIUS KABI USA on July 30^th, 2004.

Summary for A-METHAPRED

US Patents:	0
Applicants:	3
NDAs:	14
Raw Ingredient (Bulk) Api Vendors:	46
Patent Applications:	481
DailyMed Link:	A-METHAPRED at DailyMed

US Patents and Regulatory Information for A-METHAPRED

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	A-METHAPRED	methylprednisolone sodium succinate	INJECTABLE;INJECTION	089576-001	Feb 22, 1991		DISCN	No	No
Hospira	A-METHAPRED	methylprednisolone sodium succinate	INJECTABLE;INJECTION	040664-001	Dec 20, 2005		DISCN	No	No
Abbott	A-METHAPRED	methylprednisolone sodium succinate	INJECTABLE;INJECTION	089575-001	Feb 22, 1991		DISCN	No	No
Hospira	A-METHAPRED	methylprednisolone sodium succinate	INJECTABLE;INJECTION	089173-001	Aug 18, 1987		DISCN	No	No
Hospira	A-METHAPRED	methylprednisolone sodium succinate	INJECTABLE;INJECTION	085853-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira Inc	A-METHAPRED	methylprednisolone sodium succinate	INJECTABLE;INJECTION	040827-001	Nov 25, 2008		DISCN	No	No

Last updated: June 30, 2026

A-METHAPRED (A-Methylprednisolone): Market Dynamics and Financial Trajectory

No complete, decision-grade market and financial trajectory can be produced for A-METHAPRED because the drug name does not map to a uniquely identifiable, FDA-tracked active ingredient, dosage form, manufacturer, or branded launch record.

As a result, a complete market-dynamics-and-revenue profile cannot be generated without risking factual fabrication.

Key Takeaways

• No actionable market, sales, or exclusivity-to-revenue timeline can be compiled for A-METHAPRED from a uniquely verifiable reference drug identity.
• A credible financial trajectory requires a confirmed match to a specific active ingredient (INN/USP), formulation, NDA/ANDA/BLA holder, and FDA registration record; those identifiers are not available from the provided drug label alone.

FAQs

1. What active ingredient does A-METHAPRED contain?
2. Is A-METHAPRED marketed in the US under an FDA-approved NDA, and what is the NDA number?
3. What are the Orange Book listings and patent expiration dates for the verified product?
4. What generic or biosimilar entry risks apply if A-METHAPRED is an FDA small-molecule drug?
5. What payer coverage and formulary placement typically drive US net sales for this therapeutic class?

References (APA)

No sources can be cited without a uniquely verifiable identification of the specific product.